The rotating glass sphere method for platelet adhesion rate testing is a classic in vitro hemocompatibility assay that quantifies how readily platelets adhere to artificial surfaces under controlled, low-shear dynamic contact. Positioned within the ISO 10993-4 and GB/T 16886.4 framework for evaluating interactions with blood, this test provides rapid, reproducible data for biomaterial screening, surface-modification studies, and regulatory hemocompatibility submissions for blood-contacting medical devices.
Technical Overview
The rotating glass sphere method, also known as the rotating glass bulb or rotating glass ball method, measures the platelet adhesion rate of anticoagulated whole blood following dynamic contact with a glass surface or with a test material lining the inner wall of a spherical glass vessel. Because platelet adhesion is the initiating event in thrombus formation on foreign surfaces, the adhesion rate serves as a sensitive indicator of surface thrombogenicity.
In the assay, a defined volume of citrated blood is placed inside a spherical glass vessel, which is then rotated at a constant low speed and constant temperature for a fixed contact time. During rotation, a thin film of blood repeatedly wets the entire inner wall, and a measurable fraction of the platelets adheres to the surface. Platelet counts determined before and after contact allow the adhesion rate to be calculated as a percentage.
This assay belongs to the platelet test category defined in ISO 10993-4 and GB/T 16886.4 for medical devices that contact circulating blood, and it is frequently combined with platelet morphology studies, coagulation assays, hemolysis testing, and thrombosis models to construct a complete hemocompatibility profile.
- Test category: in vitro dynamic contact platelet adhesion assay
- Governing framework: ISO 10993-4 and GB/T 16886.4; sample preparation per ISO 10993-12 and GB/T 16886.12
- Primary readout: platelet adhesion rate (%) derived from paired platelet counts
- Test duration: a single contact run completes in about 15 to 30 minutes, followed immediately by platelet counting
Testing Samples
Blood-Contacting Medical Devices
Finished devices or device components that contact circulating or recirculating blood during clinical use, including intravascular catheters, cannulae, perfusion tubing sets, blood collection bags, hemodialyzers, oxygenators, extracorporeal circuit components, syringes, infusion sets, and material forms of vascular grafts, stents, and heart valve components.
Biomaterials and Surface Coatings
Polymer films and sheets, hydrophilic or antithrombotic coatings, heparinized or otherwise surface-modified metals and alloys, ceramics, hydrogels, and functional nanocoatings. Samples are typically cut into defined pieces or coated directly onto the interior wall of the glass sphere so that the blood contacts only the test surface during rotation.
Blood Source
Fresh whole blood from healthy human volunteers, or animal blood such as rabbit or ovine blood where scientifically justified, is collected with minimal trauma using a wide-bore needle, discarding the initial portion of the draw to avoid tissue factor contamination. Donors should have taken no antiplatelet or anticoagulant medication for at least 7 to 14 days before sampling. Sodium citrate anticoagulation, for example 3.2 percent trisodium citrate at a 1:9 citrate-to-blood ratio, preserves physiological platelet responsiveness during the contact phase, while EDTA is used only afterward to stabilize samples for counting.
Control Materials
- Positive control: untreated borosilicate glass, a strongly platelet-adhesive reference surface
- Negative control: a low-thrombogenic reference polymer such as polyethylene or medical-grade silicone
- Optional baseline: an untreated glass sphere to characterize the intrinsic platelet adhesiveness of the donor blood
Testing Items
The core deliverable is the platelet adhesion rate, and several supporting measurements are commonly reported alongside it to strengthen interpretation.
- Baseline platelet count before contact and residual platelet count after contact with each surface
- Platelet adhesion rate (%) for the test material, positive control, and negative control
- Comparative ranking of test surfaces against controls using replicate measurements
- Optional: morphology of adhered platelets by scanning electron microscopy, including shape change, spreading, pseudopod extension, and aggregation, as evidence of activation
- Optional complementary markers: platelet activation markers such as P-selectin (CD62P) by flow cytometry, platelet-leukocyte aggregates, or plasma markers of platelet release
Testing Methods
Test Principle
When anticoagulated blood is rotated inside a spherical glass vessel, platelets contact the wall repeatedly under low-shear dynamic conditions, and a fraction of them adhere to the surface. The reduction in platelet concentration relative to the initial count, expressed as a percentage, defines the platelet adhesion rate for that surface.
Standard Procedure
- Collect venous blood into sodium citrate anticoagulant, avoiding hemolysis, foaming, and premature activation.
- Prepare the glass spheres: keep one uncoated as the reference and positive control, line others with the test material film or coating, and prepare negative control spheres as applicable.
- Equilibrate the blood and the vessels at 37 degrees Celsius.
- Transfer a defined blood volume, commonly 1.0 mL, into each sphere, maintaining a consistent volume-to-surface-area ratio across all vessels.
- Rotate the spheres at a constant low speed, typically 3 to 5 rpm, for a fixed contact time of typically 10 to 15 minutes in a temperature-controlled rotator.
- Immediately transfer the post-contact blood into EDTA-containing tubes to terminate the adhesion process and stabilize the sample.
- Determine platelet counts using a calibrated hematology analyzer, flow cytometric platelet counting based on CD41 or CD61 staining, or manual phase-contrast chamber counting, within the validated time window.
- Run replicate spheres and paired controls for each blood draw to support statistical comparison.
Calculation
Platelet adhesion rate (%) = (P0 minus P1) divided by P0, multiplied by 100, where P0 is the platelet count of the blood before contact and P1 is the platelet count after contact with the test surface. Results are typically reported as the mean and standard deviation of replicates, with the test material compared against the positive and negative controls from the same blood draw.
Quality Control and Key Influencing Factors
- Rotation speed, contact time, temperature, and the blood volume-to-surface ratio must be strictly controlled and documented because they directly affect the adhesion rate.
- Pre-analytical variables such as tourniquet time, needle gauge, draw sequence, and resting time before testing strongly influence platelet reactivity.
- Donor platelet count, hematocrit, and medication status affect absolute values, so paired control surfaces tested in the same blood draw are essential for valid comparison.
- Platelet counting should be completed promptly, and the counting method must be validated for post-contact samples.
- Under classic clinical conditions, healthy human blood typically shows an adhesion rate of approximately 20 to 40 percent against bare glass; each laboratory should establish its own control limits through historical data.
Applications
The rotating glass sphere platelet adhesion test is widely applied across the medical device and biomaterial value chain, from early research to market approval and routine quality control.
- Research and development screening of candidate polymers, alloys, ceramics, and surface coatings for blood compatibility
- Comparative evaluation of surface modification strategies such as heparinization, hydrophilic coating, zwitterionic grafting, and texturing
- Regulatory hemocompatibility packages for blood-contacting devices under the ISO 10993 series, submitted to authorities such as China NMPA, the US FDA, and EU notified bodies
- Batch-to-batch quality control for coated tubing, catheters, and blood-contacting consumables
- Academic and industrial studies of platelet-surface interactions, thrombogenicity mechanisms, and antiplatelet surface design
- Comparative benchmarking of competitor-equivalent materials during product development
FAQ
What does a high platelet adhesion rate indicate?
A high adhesion rate indicates that a large proportion of platelets adhered to the test surface, reflecting higher thrombogenic potential and poorer blood compatibility. A low rate indicates that the surface resists platelet adhesion and is generally more favorable for blood-contacting applications.
Why is a rotating glass sphere used as the test vessel?
The spherical geometry allows a small blood volume to wet the entire inner surface reproducibly during slow rotation, creating controlled and repeatable dynamic contact. Bare glass also provides a stable, strongly platelet-adhesive reference surface, making it an effective positive control.
Which anticoagulants are used and at what stage?
Sodium citrate is used during the contact phase because it preserves the divalent-cation-dependent adhesion mechanisms of platelets. EDTA is added only after contact to stop further adhesion and to stabilize the sample for accurate platelet counting.
How does this method compare with other platelet adhesion tests?
Compared with glass bead column methods, parallel-plate flow chambers, or Chandler loop systems, the rotating sphere method is simpler, faster, and requires only a small blood volume, but it operates at low shear and does not fully reproduce arterial flow conditions. Flow-based methods are preferred when shear-dependent behavior is critical, while the rotating sphere method is well suited to rapid material screening and comparative ranking.
Can animal blood be used instead of human blood?
Yes, when scientifically justified and ethically approved, animal blood such as rabbit or ovine blood can be used, particularly for early screening. Species differences in platelet reactivity must be considered, and human blood is preferred for results intended to support clinical relevance claims.
Which standards govern this test?
ISO 10993-4 and its Chinese counterpart GB/T 16886.4 define the categories of blood-interaction tests, including platelet assays, and guide the selection of appropriate testing based on device contact type and duration. ISO 10993-12 and GB/T 16886.12 address sample preparation, while detailed operating parameters typically follow validated laboratory procedures based on classical hematology methods.
Is there a universal pass or fail criterion?
No universal acceptance limit exists. Results are interpreted comparatively against positive and negative controls run in parallel, and product-specific criteria are defined by the manufacturer within the biological evaluation plan and risk management file, consistent with ISO 10993-1 and ISO 14971.